Press release
The Respiratory Syncytial Virus Market Size in the 7MM was observed to be ~USD 1,200 million in 2022 | Major Companies- Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and Others
The Respiratory Syncytial Virus Market research report conducts a careful market evaluation and provides a professional analysis of the industry taking into account market development, present market circumstances, and forecasts for the future. The Respiratory Syncytial Virus market driving factors, market overview, industry volume, and market share are also highlighted in this Respiratory Syncytial Virus Market report analysis.
Key Takeaways from the Respiratory Syncytial Virus Market Report
• In 2022, the total incident cases of Respiratory Syncytial Virus in the 7MM were ~8,495,000, and these cases are anticipated to increase during the study period.
• In 2022, as per the severity of Respiratory Syncytial Virus infection in children, mild, moderate, and severe cases formed 70%, 27%, and 3% of the total incident cases of Respiratory Syncytial Virus in the US, respectively.
• The market size of the Respiratory Syncytial Virus in the 7MM was observed to be ~USD 1,200 million in 2022.
• The leading Respiratory Syncytial Virus Companies include Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and Others
• Promising Respiratory Syncytial Virus Pipeline Therapies include Nirsevimab, AK0529, Palivizumab, Suptavumab 30 mg/kg, and others
Explore more information about the Latest Drugs Launch, New Breakthroughs of Drugs or Therapies Approaches, Treatment Practices, and Forecasted Epidemiology @ Respiratory Syncytial Virus Market Size- https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Respiratory Syncytial Virus Overview
Respiratory Syncytial Virus is a common respiratory virus that infects the nose, throat, lungs, and breathing passages. Respiratory Syncytial Virus belongs to the genus Orthopneumovirus within the family Pneumoviridae and order Mononegavirales. Members of this genus include human Respiratory Syncytial Virus, bovine Respiratory Syncytial Virus, and murine pneumonia virus.
Respiratory Syncytial Virus Epidemiology Segmentation in the 7MM
• Respiratory Syncytial Virus Patient Pool
• Respiratory Syncytial Virus Forecasted Trends
Download the report to understand which factors are driving Respiratory Syncytial Virus epidemiology trends @ Respiratory Syncytial Virus Epidemiological Insights- https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Respiratory Syncytial Virus Marketed Drugs
• SYNAGIS (palivizumab): Swedish Orphan Biovitrum AB (SOBI):
Palivizumab is a humanized monoclonal antibody (IgG1?) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of Respiratory Syncytial Virus. SYNAGIS is supplied as a sterile, preservative-free liquid solution at 100 mg per mL to be administered by intramuscular injection. In June 1998, SYNAGIS was approved to prevent serious lower respiratory tract disease caused by Respiratory Syncytial Virus in pediatric patients in the US.
Respiratory Syncytial Virus Emerging Drugs
Respiratory Syncytial ViruspreF (PF-06928316): Pfizer
Pfizer's investigational Respiratory Syncytial Virus vaccine candidate, Respiratory Syncytial ViruspreF, builds on foundational basic science discoveries, including those made at the National Institutes of Health (NIH), which detailed the crystal structure of prefusion F, a key form of the viral fusion protein (F) that Respiratory Syncytial Virus uses to attack human cells. In March 2022, Pfizer announced that its Respiratory Syncytial Virus vaccine candidate, PF-06928316 or Respiratory Syncytial ViruspreF, received BTD from the US FDA to prevent lower respiratory tract disease caused by Respiratory Syncytial Virus in individuals 60 years or older.
Respiratory Syncytial VirusPreF3 (GSK3844766A) Vaccine: GlaxoSmithKline
GSK3844766A contains a recombinant subunit pre-fusion Respiratory Syncytial Virus antigen combined with GSK's proprietary AS01 adjuvant, which is also used in the company's shingles vaccine. The drug has accepted regulatory submissions in Europe and Japan for older adults aged 60+. The Regulatory decision in the US is expected in the first half of 2023. US FDA has set a Prescription Drug User Fee Act action date of May 2023.
mRNA-1345: Moderna
The mRNA-1345 vaccine is a messenger RNA (mRNA) vaccine. This mRNA is entirely made in a laboratory and instructs the body to build small pieces of proteins. Moderna's mRNA-1345 Respiratory Syncytial Virus vaccine candidate encodes for a prefusion F glycoprotein, eliciting a superior neutralizing antibody response. In August 2021, Moderna received the FDA's FTD for the Respiratory Syncytial Virus vaccine (mRNA-1345) in adults older than 60.
Respiratory Syncytial Virus Market Outlook
While understanding Respiratory Syncytial Virus pathogenesis and viral biology has increased over time, prevention of the virus is still lacking, often with severe disease burdens. Treatment for Respiratory Syncytial Virus infection is currently limited to supportive care and prophylactic antibody use. It may include hydration, supplemental oxygen, suctioning of airways, and mechanical ventilation when needed.
Learn more about the FDA-approved drugs for Respiratory Syncytial Virus @ Respiratory Syncytial Virus Market Drivers and Barriers- https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Respiratory Syncytial Virus Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Respiratory Syncytial Virus Companies- Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and Others
• Respiratory Syncytial Virus Pipeline Therapies- Nirsevimab, AK0529, Palivizumab, Suptavumab 30 mg/kg, and others
• Respiratory Syncytial Virus Market Dynamics: Respiratory Syncytial Virus Market Drivers and Barriers
Discover more about Respiratory Syncytial Virus Drugs in development @ Respiratory Syncytial Virus Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Key Insights
2. Report Introduction
3. Respiratory Syncytial Virus (RSV) Market Overview at a Glance
4. Executive Summary of Respiratory Syncytial Virus (RSV)
5. Key Events
6. Disease Background and Overview
7. Treatment and Management
8. Methodology
9. Epidemiology and Patient Population
10. Patient Journey
11. Marketed Products
12. Emerging Therapies
13. Respiratory Syncytial Virus (RSV) Seven Major Market Analysis
14. Market Access and Reimbursement
15. RSV Reimbursement
16. KOL Views
17. Unmet Needs
18. SWOT Analysis
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight
Got Queries? Reach out for more information about the Patient Population, Treatment Algorithm, Unmet Needs, and Emerging Drugs of the report @ Respiratory Syncytial Virus Market Dynamics- https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09193216187
Address: 304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The Respiratory Syncytial Virus Market Size in the 7MM was observed to be ~USD 1,200 million in 2022 | Major Companies- Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and Others here
News-ID: 3053104 • Views: …
More Releases from DelveInsight Business Research
Spasticity Clinical Pipeline 2025: A Comprehensive Review of 12+ Emerging Therap …
According to DelveInsight's latest analysis, the global Spasticity pipeline features more than 10 active pharmaceutical companies that are advancing over 12 investigational therapies. The report offers a detailed evaluation of clinical trials, mechanisms of action, therapeutic approaches, routes of administration, and major developmental activities shaping the Spasticity treatment landscape.
DelveInsight's report, "Spasticity Pipeline Insight, 2025," delivers an extensive overview of the current clinical development environment and the future outlook for the…
Real-World Evidence Solution Market is set to grow at a 8.07% CAGR, reaching USD …
According to DelveInsight, the real-world evidence (RWE) solutions market is expanding rapidly, primarily due to the increasing global burden of chronic diseases and the growing need to improve healthcare outcomes. In addition, advancements in big data analytics, artificial intelligence, and machine learning are enhancing the ability to efficiently process and interpret large-scale real-world datasets. The rising adoption of RWE solutions by pharmaceutical and biotechnology companies - to support drug development,…
Spinal Implants Market is set to grow at a 5.50% CAGR, reaching USD 21.9 billion …
According to DelveInsight's assessment, the rising burden of spinal disorders particularly within the growing elderly population - continues to significantly increase the demand for surgical correction procedures. Alongside this, the surge in sports-related injuries and trauma cases is accelerating the need for advanced implantable spinal solutions. There is also a notable shift toward non-fusion and motion-preserving devices that support spinal flexibility and enhance patient outcomes, especially for younger and more…
Vascular Stents Market is set to grow at a 6.65% CAGR, reaching USD 18.28 billio …
According to DelveInsight's assessment, the rising global burden of cancer is significantly increasing the demand for advanced treatment approaches such as tumor ablation. Minimally invasive ablation techniques are gaining strong traction due to their advantages, including faster recovery times, lower complication risks, and reduced costs compared with traditional surgical procedures. At the same time, continuous improvements in ablation technologies - particularly in radiofrequency, microwave, and cryoablation systems - have enhanced…
More Releases for Respiratory
Prevalence Of Respiratory Diseases Fuels Demand For Respiratory Disposables: Key …
The Respiratory Disposables Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Respiratory Disposables Market Size During the Forecast Period?
The respiratory disposables market has seen rapid growth in recent years. It is expected to grow from $1.01 billion in 2024 to $1.15…
Transforming the Respiratory Monitoring Devices Market in 2025: Rising Incidence …
What Is the Expected Size and Growth Rate of the Respiratory Monitoring Devices Market?
The market size for respiratory monitoring devices has seen swift expansion in the recent past. The market's growth is projected to increase from $1.67 billion in 2024 to $1.87 billion in 2025, with a compound annual growth rate (CAGR) of 11.8%. A combination of factors such as the prevalence of respiratory ailments, an aging demographic, technological innovations,…
Transforming the Respiratory Monitoring Devices Market in 2025: Rising Incidence …
What Is the Expected Size and Growth Rate of the Respiratory Monitoring Devices Market?
The market size for respiratory monitoring devices has seen swift expansion in the recent past. The market's growth is projected to increase from $1.67 billion in 2024 to $1.87 billion in 2025, with a compound annual growth rate (CAGR) of 11.8%. A combination of factors such as the prevalence of respiratory ailments, an aging demographic, technological innovations,…
Molecular Respiratory Panels Market: Enhancing Accuracy and Speed in Respiratory …
Introduction
The global molecular respiratory panels market is rapidly evolving, driven by the need for faster, more accurate diagnostics in respiratory diseases. With respiratory infections and diseases becoming increasingly prevalent worldwide, accurate detection and timely diagnosis are critical to improving patient outcomes. Molecular respiratory panels, which utilize advanced molecular techniques like PCR (Polymerase Chain Reaction) and other nucleic acid-based methods, enable the rapid identification of pathogens responsible for respiratory conditions. These…
Tackling Respiratory Challenges: Lower Respiratory Tract Therapeutics Market 202 …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Lower Respiratory Tract Therapeutics Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $48.37 billion In…
Respiratory Assist Devices Market - Breathing Uninterrupted: Innovating Respirat …
Newark, New Castle, USA - new report, titled Respiratory Assist Devices Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Respiratory Assist Devices market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Respiratory Assist Devices market. The report offers an overview of…
